Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Angola Calls for Equity in Vaccine Distribution

05/14/2021 | 11:06am EDT

Angolan head of State João Lourenço Thursday appealed to the countries' sensitivity in producing Covid-19 vaccines to ensure that the vaccine efforts prioritise all countries equally.

Joao Lourenço was speaking to the press shortly after he received the first dose of the vaccine in one of the four vaccination points opened in Luanda.

The president, who was accompanied by the first lady Ana Dias Lourenço, said that combined effort was crucial to combat the pandemic.

He said that it was necessary the producing countries bear in mind that no one is going to be saved alone: "We all save ourselves, rich and poor, powerful and non-powerful, or nobody will save", he said.

President João Lourenço justifies that not all countries, especially Africans, have the financial resources to purchase vaccines at the current prices.

Despite this situation, the Head of State was optimistic about the solution to this issue in the short term.

As for Angola, the president revealed that the country received 600,000 doses of AstraZeneca (in the framework of the Covax initiative) and 200,000 doses of offer from the Chinese Government.

However, Angola has received other offers in small quantities, including from business groups, to the extent of its possibilities.

The Head of State said he was aware that the Angolan Government cannot rely only on offers. "We have to buy vaccines and this effort is being made, despite the difficulties".

João Lourenço said that Angola also acquired six million doses of Sputnik V, which are still insufficient for current needs.

The current vaccination plan foresees to immunize about 54 percent of the Angolan population, the equivalent of 16.8 million.

Joao Lourenço was speaking to the press shortly after he received the first dose of the vaccine in one of the four vaccination points opened in Luanda.

The president, who was accompanied by the first lady Ana Dias Lourenço, said that combined effort was crucial to combat the pandemic.

He said that it was necessary the producing countries bear in mind that no one is going to be saved alone: "We all save ourselves, rich and poor, powerful and non-powerful, or nobody will save", he said.

President João Lourenço justifies that not all countries, especially Africans, have the financial resources to purchase vaccines at the current prices.

Despite this situation, the Head of State was optimistic about the solution to this issue in the short term.

As for Angola, the president revealed that the country received 600,000 doses of AstraZeneca (in the framework of the Covax initiative) and 200,000 doses of offer from the Chinese Government.

However, Angola has received other offers in small quantities, including from business groups, to the extent of its possibilities.

The Head of State said he was aware that the Angolan Government cannot rely only on offers. "We have to buy vaccines and this effort is being made, despite the difficulties".

João Lourenço said that Angola also acquired six million doses of Sputnik V, which are still insufficient for current needs.

The current vaccination plan foresees to immunize about 54 percent of the Angolan population, the equivalent of 16.8 million.

Copyright Angola Press Agency. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

All news about ASTRAZENECA PLC
04:08aER+/ HER2-VE BREAST CANCER PIPELINE : Emerging Therapies and Key pharma players ..
AQ
01:30aASTRAZENECAá : COVID-19 Approved In Pakistan For People Under 40
MT
06/15US, EU Vow to Provide COVID-19 Vaccine to Two-Thirds of World's Population by..
MT
06/15INDIAN SCIENTISTS : We didn't back doubling of vaccine dosing gap
RE
06/15European Stocks End Higher as Investors Wait for Fed
MT
06/15ASTRAZENECAá : How UK PM Johnson decided to delay COVID reopening
RE
06/15INDIAN SCIENTISTS : We didn't back doubling of vaccine dosing gap
RE
06/15GLOBAL MARKETS LIVE : General Electric, AstraZeneca, H&M, Bohoo, Implenia...
06/15Mitsubishi UFG Says Sterling's Positive Outlook Clouded by Spread of COVID-19..
MT
06/15WALL STREET STOCK EXCHANGE : Inflation and pricing power
More news
Financials (USD)
Sales 2021 31 008 M - -
Net income 2021 4 562 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 33,9x
Yield 2021 2,43%
Capitalization 154 B 154 B -
EV / Sales 2021 5,32x
EV / Sales 2022 4,67x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 132,34 $
Last Close Price 117,47 $
Spread / Highest target 45,5%
Spread / Average Target 12,7%
Spread / Lowest Target -18,1%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC13.91%154 316
JOHNSON & JOHNSON4.52%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.7.55%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.8.10%204 582